US Stock Reports, Quotes and News
Dr Lal PathLabs saw an 8% surge in shares to Rs 2,539.65 on the BSE following a 51% YoY increase in net profit to Rs 86 crore for Q4FY24. Analysts have varying opinions, with Kotak and JM Financial maintaining positive outlooks, while Goldman Sachs remains cautious.
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
“Till Nifty is holding about 22,500, 22,400, trend is likely to remain on the bullish side and buy on dip should be your strategy. On the higher side, once again, Nifty spot manages to cross above 22,650, 22,700, then this rally can extend further and a possible target we could see towards the 22,800 to 23,000 level.”